» Articles » PMID: 34681922

The Role of Mitochondria in Acute Kidney Injury and Chronic Kidney Disease and Its Therapeutic Potential

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Oct 23
PMID 34681922
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondria are heterogeneous and highly dynamic organelles, playing critical roles in adenosine triphosphate (ATP) synthesis, metabolic modulation, reactive oxygen species (ROS) generation, and cell differentiation and death. Mitochondrial dysfunction has been recognized as a contributor in many diseases. The kidney is an organ enriched in mitochondria and with high energy demand in the human body. Recent studies have been focusing on how mitochondrial dysfunction contributes to the pathogenesis of different forms of kidney diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD). AKI has been linked to an increased risk of developing CKD. AKI and CKD have a broad clinical syndrome and a substantial impact on morbidity and mortality, encompassing various etiologies and representing important challenges for global public health. Renal mitochondrial disorders are a common feature of diverse forms of AKI and CKD, which result from defects in mitochondrial structure, dynamics, and biogenesis as well as crosstalk of mitochondria with other organelles. Persistent dysregulation of mitochondrial homeostasis in AKI and CKD affects diverse cellular pathways, leading to an increase in renal microvascular loss, oxidative stress, apoptosis, and eventually renal failure. It is important to understand the cellular and molecular events that govern mitochondria functions and pathophysiology in AKI and CKD, which should facilitate the development of novel therapeutic strategies. This review provides an overview of the molecular insights of the mitochondria and the specific pathogenic mechanisms of mitochondrial dysfunction in the progression of AKI, CKD, and AKI to CKD transition. We also discuss the possible beneficial effects of mitochondrial-targeted therapeutic agents for the treatment of mitochondrial dysfunction-mediated AKI and CKD, which may translate into therapeutic options to ameliorate renal injury and delay the progression of these kidney diseases.

Citing Articles

Global research trends on the associations between chronic kidney disease and mitochondria: insights from the bibliometric analysis.

Tang X, Zhang A, Feng X, Wang W, Chen F, Tao Y Int Urol Nephrol. 2025; .

PMID: 40019610 DOI: 10.1007/s11255-025-04437-x.


Comment on 'the relationship between kidney disease and mitochondria: a bibliometric study'.

Wang G, Mu W, Zhang T Ren Fail. 2025; 47(1):2460747.

PMID: 39995106 PMC: 11864025. DOI: 10.1080/0886022X.2025.2460747.


The temporal relationship between mitochondrial quality and renal tissue recovery following ischemia-reperfusion injury.

Prem P, Swaminathan H, Kurian G Heliyon. 2025; 11(1):e41634.

PMID: 39866419 PMC: 11758212. DOI: 10.1016/j.heliyon.2025.e41634.


Butyrolactone I blocks the transition of acute kidney injury to chronic kidney disease in mice by targeting JAK1.

Zhang Z, Zhao Z, Qi C, Zhang X, Xiao Y, Chen C MedComm (2020). 2025; 6(2):e70064.

PMID: 39845897 PMC: 11751251. DOI: 10.1002/mco2.70064.


Aldehyde Dehydrogenase 2 Lactylation Aggravates Mitochondrial Dysfunction by Disrupting PHB2 Mediated Mitophagy in Acute Kidney Injury.

Li J, Shi X, Xu J, Wang K, Hou F, Luan X Adv Sci (Weinh). 2024; 12(8):e2411943.

PMID: 39737891 PMC: 11848585. DOI: 10.1002/advs.202411943.


References
1.
Singh S, Tao S, Fields T, Webb S, Harris R, Rao R . Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia-reperfusion in mice. Dis Model Mech. 2015; 8(8):931-40. PMC: 4527294. DOI: 10.1242/dmm.020511. View

2.
Gu X, Liu Y, Wang N, Zhen J, Zhang B, Hou S . Transcription of MRPL12 regulated by Nrf2 contributes to the mitochondrial dysfunction in diabetic kidney disease. Free Radic Biol Med. 2021; 164:329-340. DOI: 10.1016/j.freeradbiomed.2021.01.004. View

3.
Thome T, Kumar R, Burke S, Khattri R, Salyers Z, Kelley R . Impaired muscle mitochondrial energetics is associated with uremic metabolite accumulation in chronic kidney disease. JCI Insight. 2020; 6(1). PMC: 7821598. DOI: 10.1172/jci.insight.139826. View

4.
Cassidy-Stone A, Chipuk J, Ingerman E, Song C, Yoo C, Kuwana T . Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell. 2008; 14(2):193-204. PMC: 2267902. DOI: 10.1016/j.devcel.2007.11.019. View

5.
Rahman M, Shad F, Smith M . Acute kidney injury: a guide to diagnosis and management. Am Fam Physician. 2012; 86(7):631-9. View